Loading...
Loading...
NPS Pharmaceuticals
NPSP
today announced that the U.S. Food and Drug Administration (FDA) has notified
the Company that its New Drug Application (NDA) for Gattex® (teduglutide) will
be discussed at the Gastrointestinal Drugs Advisory Committee meeting
scheduled for October 16, 2012. The Prescription Drug User Fee Act (PDUFA)
date for completion of review by the FDA is December 30, 2012.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in